- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | RenovoRx, Inc.: Northwell Health Cancer Institute Launches Patient Enrollment in RenovoRx's Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial | 1 | GlobeNewswire (USA) | ||
| 14.11. | RenovoRx reports Q3 results | 1 | Seeking Alpha | ||
| 14.11. | RenovoRx, Inc.: RenovoRx Reports Third Quarter 2024 Financial Results and Operational Highlights | 43 | GlobeNewswire (Europe) | Near-Term Revenue Potential with Commercialization Plan for FDA-Cleared RenovoCath® Delivery System in Both Direct and Commercial Partner Channels Renowned Clinical Oncology Sites Participating in... ► Artikel lesen | |
| 14.11. | RenovoRx, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 25.09. | RenovoRx, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 25.09. | RenovoRx to increase production of RenovoCath catheter delivery system | 1 | MassDevice | ||
| RENOVORX Aktie jetzt für 0€ handeln | |||||
| 25.09. | RenovoRx ramps up production of RenovoCath system | 1 | Investing.com | ||
| 25.09. | RenovoRx steigert Produktion des RenovoCath-Systems | 1 | Investing.com Deutsch | ||
| 25.09. | RenovoRx, Inc.: RenovoRx Increases Production of FDA-Cleared RenovoCath Delivery System in Response to Strong Demand from Oncology and Interventional Radiology Physicians | 199 | GlobeNewswire (Europe) | LOS ALTOS, Calif., Sept. 25, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or the "Company") (Nasdaq: RNXT), a life sciences company developing novel targeted oncology therapies based on a local... ► Artikel lesen | |
| 19.09. | RenovoRx, Inc.: RenovoRx Announces Presentation at Symposium on Clinical Interventional Oncology Highlighting TAMP for Targeted Treatment of Locally Advanced Pancreatic Cancer | 3 | GlobeNewswire (USA) | ||
| 27.08. | RenovoRx, Inc.: RenovoRx CEO Shaun Bagai to Present at H.C. Wainwright's 26th Annual Global Investment Conference on September 9, 2024 in New York | 1 | GlobeNewswire (USA) | ||
| 16.08. | RenovoRx, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 14.08. | RenovoRx, Inc.: RenovoRx Announces First Patient Enrolled at University of Nebraska Medical Center for the Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial | 1 | GlobeNewswire (USA) | ||
| 13.08. | RenovoRx, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 08.07. | RenovoRx, Inc.: RenovoRx Announces Acceptance for Publication in the International Peer-Reviewed Journal, The Oncologist® | 1 | GlobeNewswire (USA) | ||
| 26.06. | RenovoRx, Inc.: University of Nebraska Medical Center Launches Patient Enrollment for RenovoRx's Pivotal Phase III TIGeR-PaC Clinical Trial | 1 | GlobeNewswire (USA) | ||
| 10.06. | RenovoRx, Inc.: RenovoRx Appoints Ryan Witt as Senior Vice President, Head of Corporate Strategy and Partnerships | 2 | GlobeNewswire (USA) | ||
| 07.06. | RenovoRx, Inc. - 8-K, Current Report | 1 | SEC Filings |
18 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EPIGENOMICS | 0,900 | -21,74 % | EQS-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß § 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: Epigenomics AG
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
Epigenomics AG: Vorabbekanntmachung über die... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,384 | +3,78 % | Defence Therapeutics Inc.: Defence Therapeutics Announces Securities for Debenture Financing | Vancouver, British Columbia--(Newsfile Corp. - November 14, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company... ► Artikel lesen | |
| GINKGO BIOWORKS | 6,000 | -0,83 % | Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Sees Significant Drop in Short Interest | ||
| RECURSION PHARMACEUTICALS | 5,735 | -5,05 % | Recursion Pharmaceuticals, Inc.: Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery | Recursion unveils post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 advanced discovery programs, and more than 10 partnered programsPlatform will... ► Artikel lesen | |
| BEAM THERAPEUTICS | 23,740 | -3,02 % | Beam Therapeutics Inc. (NASDAQ:BEAM) Sees Large Increase in Short Interest | ||
| ONCOLYTICS BIOTECH | 0,945 | 0,00 % | Oncolytics Biotech Inc. (NASDAQ:ONCY) Q3 2024 Earnings Call Transcript | ||
| ARCTURUS THERAPEUTICS | 16,220 | +0,19 % | Arcturus Therapeutics Holdings Inc.: Arcturus Therapeutics to Present at Jefferies London Healthcare Conference | Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities... ► Artikel lesen | |
| ASSERTIO | 0,950 | 0,00 % | Assertio Holdings-Direktorin Heather Mason kauft Aktien im Wert von 60.000 US-Dollar | ||
| SIGA TECHNOLOGIES | 6,275 | +0,40 % | SIGA Technologies - TPOXX chalks up another DoD contract win | SIGA Technologies announced another contract win with the US Department of Defense (DoD), which is for the procurement of c $9m in TPOXX. This is the third DoD contract win in roughly three years for... ► Artikel lesen | |
| ADMA BIOLOGICS | 21,250 | -0,56 % | Adma Biologics Aktie: Erholung nach starkem Kursrückgang | ||
| VIR BIOTECHNOLOGY | 6,610 | -1,93 % | Needham & Company LLC Reaffirms Buy Rating for Vir Biotechnology (NASDAQ:VIR) | ||
| VERVE THERAPEUTICS | 4,525 | -0,55 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on October 31, 2024... ► Artikel lesen | |
| TRAVERE THERAPEUTICS | 17,000 | 0,00 % | Kidney Disease Leader Travere Therapeutics Pulls Back To Key Level | ||
| ARVINAS | 23,240 | +2,42 % | Arvinas, Inc. (ARVN): This Small-Cap Stock Is Ready To Explode | ||
| BIO-PATH | 0,790 | 0,00 % | Bio-Path Holdings, Inc.: Bio-Path Holdings Reports Third Quarter 2024 Financial Results | Expands DNAbilize® Technology Beyond Oncology into Obesity Conference Call to be Held Today at 8:30 A.M. ET HOUSTON, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology... ► Artikel lesen |
Das Unternehmen RENOVORX INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 1,100 Euro und damit -7,95 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu RENOVORX INC finden Sie auf Wallstreet Online.
